Loading...
Loading...
In a note out today, Wedbush reiterated an outperform rating and $17 price target on Halozyme Therapeutics
HALO. That price target implies significant upside from where the shares closed on Tuesday.
“We arrive at our fair value estimate of $17/share by taking the sum of a 6x multiple on HALO's revenue from Hylenex in the pump setting in 2016 and a 15x multiple on royalties received from partnerships with Baxter, Roche and ViroPharma, all discounted back 5 years at 20%. We prefer to ascribe no value to the insulin pen, PEGPH20, and HTI-501 dermatology programs as well as the Interexon partnership,” Wedbush said in the note.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorNewsPrice TargetReiterationPre-Market OutlookMarketsAnalyst RatingsTrading Ideas
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in